2024
Fusobacterium nucleatum-mimicking nanovehicles to overcome chemoresistance for breast cancer treatment by eliminating tumor-colonizing bacteria
Chen L, Shen J, Kang Z, Zhang Z, Zheng Z, Zhang L, Xiao Z, Zhang Q, Fang H, Zhou J, Wang Y, Yang Y, Liu Z, Chen Q. Fusobacterium nucleatum-mimicking nanovehicles to overcome chemoresistance for breast cancer treatment by eliminating tumor-colonizing bacteria. Chem 2024, 10: 1783-1803. DOI: 10.1016/j.chempr.2024.01.030.Peer-Reviewed Original ResearchBreast cancerRegression of established tumorsLung metastasis of breast cancerMetastasis of breast cancerBroad-spectrum antibioticsBreast cancer treatmentBreast cancer chemotherapyEstablished tumorsIntratumoral microbiomeF. nucleatumLung metastasesChemotherapy efficacyOvercome chemoresistanceCancer therapyPromote chemoresistanceCancer chemotherapyCancer treatmentBreastCancerDrug delivery carriersTumorChemoresistanceDelivery carriersNanovehiclesEfficacyStrategically Staged Tumor Ablation and Inflammation Suppression Using Shell‐Core Nanoparticles to Eradicate Bladder Tumors and Prevent Recurrence
Xu Y, Zhang R, Zhu J, Guo Z, Jin D, Qian L, Yang Y, Chen H. Strategically Staged Tumor Ablation and Inflammation Suppression Using Shell‐Core Nanoparticles to Eradicate Bladder Tumors and Prevent Recurrence. Advanced Functional Materials 2024, 34 DOI: 10.1002/adfm.202402078.Peer-Reviewed Original ResearchPrevent tumor recurrenceBladder tumorsTumor recurrenceTumor ablationPreventing bladder tumor recurrenceRat bladder tumor modelBladder tumor modelBladder tumor recurrenceInflammation suppressionCancer-related inflammationRelease of nitric oxideAnti-inflammatory effectsAcidic tumor environmentTumor environmentTumor modelPrevent recurrenceReduce inflammationTumorRecurrenceInflammationReactive oxygen speciesNitric oxideIn vitroAbstract NanomedicineAnti-tumorProgrammable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy
Wang C, Chen L, Zhu J, Wang C, Li M, Miao Y, Liu N, Ji Z, Pan F, Liu Y, Zhu J, Yang Y, Chen Q. Programmable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy. Advanced Functional Materials 2024, 34 DOI: 10.1002/adfm.202316092.Peer-Reviewed Original ResearchSonodynamic therapyAntitumor immune responseTumor-associated antigensImmune memory responsePrevent tumor recurrenceInhibit tumor metastasisOrthotopic colorectal tumorsAbscopal effectTumor recurrenceEffective sonodynamic therapyTumor siteNano-sonosensitizersTumor hypoxiaPathogen-associated molecular patternsColorectal tumorsMemory responsesTherapeutic delivery systemsTumor metastasisImmune responseTumorLive biotherapeuticsMetastasisBacterial pathogen-associated molecular patternsMolecular patternsOverexpressing catalase
2023
Antibacterial Fusobacterium nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐Colonized Bacteria and Enhance Immunotherapy Against Colorectal Cancer
Chen L, Zhao R, Shen J, Liu N, Zheng Z, Miao Y, Zhu J, Zhang L, Wang Y, Fang H, Zhou J, Li M, Yang Y, Liu Z, Chen Q. Antibacterial Fusobacterium nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐Colonized Bacteria and Enhance Immunotherapy Against Colorectal Cancer. Advanced Materials 2023, 35: e2306281. PMID: 37722134, DOI: 10.1002/adma.202306281.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeF. nucleatumTumor modelTherapeutic responseResponse to immune checkpoint blockadeColorectal cancerColorectal tumorsImmunosuppressive tumor microenvironmentColorectal cancer modelAnimal tumor modelsAgainst Colorectal CancerColorectal tumor cellsICB therapyCheckpoint blockadeCancer immunotherapyTumor microenvironmentFusobacterium nucleatumMC-38Cancer modelsTumor cellsClinical evidenceTumor developmentSide effectsTumorCancer treatmentDelivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance
Chen L, Zhao R, Kang Z, Cao Z, Liu N, Shen J, Wang C, Pan F, Zhou X, Liu Z, Yang Y, Chen Q. Delivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance. Journal Of Controlled Release 2023, 363: 43-56. PMID: 37734673, DOI: 10.1016/j.jconrel.2023.09.028.Peer-Reviewed Original ResearchConceptsShort-chain fatty acid butyrateF. nucleatumFatty acid butyrateColorectal tumorsColorectal cancerInvasion of F. nucleatumTherapeutic efficacy of oxaliplatinEfficacy of oxaliplatinProgression of colorectal cancerEffect of butyrateOrthotopic colorectal tumorsFusobacterium nucleatumClinical application prospectsTherapeutic efficacyDrug resistanceIntravenous administrationColorectal cancer tissuesIntravenous injectionOral administrationCancer resistanceOral deliveryTumorKilling effectCancer tissuesChemoresistance